Pharmaceutical Industry Reports crispr and cas gene market | Page 2

REPORT DESCRIPTION
CRISPR and CAS Gene Market – Overview
Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and Huntington’s
disease worldwide is highly contributing to the market growth of CRISPR and CAS gene market, as many genetic
disabilities can be corrected using this gene editing technology. According to National Health Service (NHS) U.K.
2018 report, the highest rate of Huntington’s disease in the United Kingdom is 12 per 100,000 people. Also, in the
U.S., an estimated 10 per 100,000 have the faulty Huntington’s gene and live either waiting for symptoms to
begin or live/struggle with the disease.
Government bodies are taking initiatives for developing treatment of Huntington’s disease. For instance, in 2016,
US-based Company Addgene has developed the KamiCas9, a version of CRISPR-Cas9 that includes a ‘self-
inactivating’ KamiCas9 system for the editing of CNS disease genes for treatment of Huntington’s disease.
However, the CRISPR and CAS gene market growth is hindered by the ethical issues, which is the major concern
for every gene therapy. For instance, in April 2015, the US National Institutes of Health issued a statement
indicating that it will not fund any research that uses genome editing tools such as CRISPR in human embryos
due to ethical issues.